Journal article icon

Journal article

Novel imatinib derivatives with altered specificity between Bcr-Abl and FMS, KIT, and PDGF receptors.

Abstract:

Imatinib is a clinically important ATP analogue inhibitor that targets the tyrosine kinase domain of the intracellular Abl kinase and the PDGF receptor family. Imatinib has revolutionised the treatment of chronic myeloid leukaemia, which is caused by the oncogene Bcr-Abl and certain solid tumours that harbor oncogenic mutations of the PDGF receptor family. As a leading kinase inhibitor, imatinib also provides an excellent model system to investigate how changes in drug design impact biologica...

Expand abstract

Actions


Access Document


Publisher copy:
10.1002/cmdc.200900394

Authors


Journal:
ChemMedChem More from this journal
Volume:
5
Issue:
1
Pages:
130-139
Publication date:
2010-01-01
DOI:
EISSN:
1860-7187
ISSN:
1860-7179

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP